A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01419236
First received: August 16, 2011
Last updated: January 8, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to see if testosterone solution 2% can help symptoms of ejaculatory dysfunction in men with low testosterone.


Condition Intervention Phase
Ejaculatory Dysfunction
Hypogonadism
Drug: Testosterone Solution 2%
Drug: Placebo Solution
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Explore the Impact of Testosterone Solution 2% on Symptoms of Ejaculatory Dysfunction in Men With Testosterone Deficiency

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Change from Baseline in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Ejaculatory Function Score at 16 Weeks [ Time Frame: Baseline, 16 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from Baseline in Ejaculate Volume at 16 Weeks [ Time Frame: Baseline, 16 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Sexual Activity Log at 16 Weeks [ Time Frame: Baseline, 16 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in the International Index of Erectile Function-Orgasmic Function Domain Score at 16 Weeks [ Time Frame: Baseline, 16 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in MSHQ-EjD-SF Bother/Satisfaction Score at 16 Weeks [ Time Frame: Baseline, 16 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 146
Study Start Date: August 2011
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Testosterone Solution 2% 60 mg
Testosterone Solution 2% 60 mg applied topically once daily with possible 1-time titration to 30 mg/day or 90 mg/day for 16 weeks
Drug: Testosterone Solution 2%
Administered topically
Other Names:
  • Axiron
  • LY900011
Placebo Comparator: Placebo
Placebo solution applied topically once daily for 16 weeks
Drug: Placebo Solution
Administered topically

  Eligibility

Ages Eligible for Study:   26 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Total testosterone level <10.4 nmol/L (300 ng/dL) at screening
  • Presents with 1 or more of the following symptom(s) of ejaculatory dysfunction: delayed ejaculation, anejaculation, decreased force of ejaculation, or decreased ejaculatory volume, as determined by investigator assessment
  • Prostate-Specific Antigen (PSA) <4 ng/mL at screening

Exclusion Criteria:

  • Sexual partner who is or becomes pregnant at any time during the study
  • Premature ejaculation as determined by investigator assessment
  • Currently receiving testosterone replacement therapy or have a history of insufficient response to testosterone replacement therapy for ejaculatory dysfunction symptoms
  • Currently receiving treatment with cancer chemotherapy or antiandrogens
  • History of use of estrogenizing agents
  • Current use of warfarin
  • History of selective serotonin reuptake inhibitor (SSRI) and/or serotonin-norepinephrine reuptake inhibitor (SNRI) treatment in the 6 months prior to screening
  • History of frequent opioid use within 30 days prior to screening, with exception of treatment for chronic pain as determined by investigator.
  • Body Mass Index (BMI) >35 kg/m2 at screening
  • Significant peripheral neuropathy affecting erectile, ejaculatory, or orgasmic function
  • Hematocrit ≥50% at screening
  • Exhibit systolic blood pressure >170 mm Hg or <90 mm Hg or diastolic blood pressure >100 mm Hg or <50 mm Hg at screening (if stress is suspected, retest under basal conditions at screening), or have history of malignant hypertension
  • History of any of the following coronary conditions within 90 days of screening: Myocardial infarction, Coronary artery bypass graft surgery, Percutaneous coronary intervention (eg, angioplasty or stent placement)
  • Known or suspected carcinoma (or history of carcinoma) of the prostate or suspicious nodules on digital rectal exam at screening
  • Known or suspected breast cancer (or history of breast cancer) or other active cancer (with the exception of nonmelanotic skin cancer)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01419236

Locations
United States, California
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Los Angeles, California, United States, 90048
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Diego, California, United States, 92120
United States, Louisiana
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
New Orleans, Louisiana, United States, 70112
United States, Massachusetts
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Brookline, Massachusetts, United States, 02445
United States, New York
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Great Neck, New York, United States, 11021
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
New York, New York, United States, 10021
Canada, Quebec
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Quebec City, Quebec, Canada, G1N 4V3
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01419236     History of Changes
Other Study ID Numbers: 13981, I5E-MC-TSAB
Study First Received: August 16, 2011
Last Updated: January 8, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Mexico: Ministry of Health

Keywords provided by Eli Lilly and Company:
Ejaculatory Dysfunction
Orgasmic Dysfunction
Sexual Dysfunction
Climax Dysfunction
Erectile Dysfunction
Impotence
Hypogonadism
Low testosterone
Low t

Additional relevant MeSH terms:
Hypogonadism
Endocrine System Diseases
Gonadal Disorders
Methyltestosterone
Pharmaceutical Solutions
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Anabolic Agents
Androgens
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014